Literature DB >> 25961642

Anti-Inflammatory Activity in the Low Molecular Weight Fraction of Commercial Human Serum Albumin (LMWF5A).

Gregory W Thomas1,2,3, Leonard T Rael1,2,3, Charles W Mains2,4, Denetta Slone1,4, Matthew M Carrick3, Raphael Bar-Or1,2,3, David Bar-Or1,2,3,4.   

Abstract

The innate immune system is increasingly being recognized as a critical component in osteoarthritis (OA) pathophysiology. An ex vivo immunoassay utilizing human peripheral blood mononuclear cells (PBMC) was developed in order to assess the OA anti-inflammatory properties of the low molecular weight fraction (<5 kDa) of commercial human serum albumin (LMWF5A). PBMC from various donors were pre-incubated with LMWF5A before LPS stimulation. TNFα release was measured by ELISA in supernatants after an overnight incubation. A ≥ 30% decrease in TNFα release was observed. This anti-inflammatory effect is potentially useful in assessing potency of LMWF5A for the treatment of OA.

Entities:  

Keywords:  human serum albumin; lipopolysaccharide; osteoarthritis; peripheral blood mononuclear cells; tumor necrosis factor α

Mesh：

Substances：

Year:  2016        PMID： 25961642     DOI： 10.1080/15321819.2015.1047516

Source DB:  PubMed          Journal:  J Immunoassay Immunochem        ISSN： 1532-1819


  8 in total

1.  Incidence of total knee replacement subsequent to intra-articular injection of the anti-inflammatory compound LMWF-5A versus saline: a long-term follow-up study to a randomized controlled trial.

Authors:  John Schwappach; Joseph Schultz; Kristin Salottolo; David Bar-Or
Journal:  Patient Saf Surg       Date:  2018-06-04

2.  Intra-articular injection of the anti-inflammatory compound LMWF-5A in adults with severe osteoarthritis: a double-blind prospective randomized controlled multi-center safety and efficacy trial.

Authors:  Kristin Salottolo; Brian Cole; David Bar-Or
Journal:  Patient Saf Surg       Date:  2018-06-18

3.  The low molecular weight fraction of human serum albumin upregulates COX2, prostaglandin E2, and prostaglandin D2 under inflammatory conditions in osteoarthritic knee synovial fibroblasts.

Authors:  Elizabeth D Frederick; Melissa A Hausburg; Gregory W Thomas; Leonard T Rael; Edward Brody; David Bar-Or
Journal:  Biochem Biophys Rep       Date:  2016-08-12

4.  The novel immunomodulatory biologic LMWF5A for pharmacological attenuation of the "cytokine storm" in COVID-19 patients: a hypothesis.

Authors:  Gregory Thomas; Elizabeth Frederick; Melissa Hausburg; Laura Goldberg; Marshall Hoke; Michael Roshon; Charles Mains; David Bar-Or
Journal:  Patient Saf Surg       Date:  2020-05-13

5.  LMWF5A suppresses cytokine release by modulating select inflammatory transcription factor activity in stimulated PBMC.

Authors:  Gregory Thomas; Elizabeth Frederick; Lisa Thompson; Raphael Bar-Or; Yetti Mulugeta; Melissa Hausburg; Michael Roshon; Charles Mains; David Bar-Or
Journal:  J Transl Med       Date:  2020-11-30       Impact factor: 5.531

6.  AMP5A modulates Toll-like receptors 7 and 8 single-stranded RNA immune responses in PMA-differentiated THP-1 and PBMC.

Authors:  Gregory Thomas; Kristen Hirter; Elizabeth Frederick; Melissa Hausburg; Raphael Bar-Or; Yetti Mulugeta; Michael Roshon; Charles Mains; David Bar-Or
Journal:  Transl Med Commun       Date:  2022-03-03

7.  The anti-inflammatory effect of LMWF5A and N-acetyl kynurenine on macrophages: Involvement of aryl hydrocarbon receptor in mechanism of action.

Authors:  Leonard T Rael; Raphael Bar-Or; Kaysie L Banton; Charles W Mains; Michael Roshon; Allen H Tanner; Mark J Lieser; David L Acuna; David Bar-Or
Journal:  Biochem Biophys Rep       Date:  2018-07-11

8.  AMBAR, an Encouraging Alzheimer's Trial That Raises Questions.

Authors:  David A Loeffler
Journal:  Front Neurol       Date:  2020-05-29       Impact factor: 4.003
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.